Precision BioSciences, Inc. (DTIL): Price and Financial Metrics

Precision BioSciences, Inc. (DTIL): $1.30

-0.01 (-0.76%)

POWR Rating

Component Grades













Add DTIL to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where DTIL ranks best; there it ranks ahead of 80.27% of US stocks.
  • The strongest trend for DTIL is in Value, which has been heading down over the past 177 days.
  • DTIL ranks lowest in Momentum; there it ranks in the 3rd percentile.

DTIL Stock Summary

  • Revenue growth over the past 12 months for PRECISION BIOSCIENCES INC comes in at -62.99%, a number that bests only 2.63% of the US stocks we're tracking.
  • The volatility of PRECISION BIOSCIENCES INC's share price is greater than that of 96.61% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DTIL comes in at -85.4% -- higher than that of only 6.69% of stocks in our set.
  • Stocks that are quantitatively similar to DTIL, based on their financial statements, market capitalization, and price volatility, are MRUS, VXRT, FDMT, MRKR, and AGIO.
  • DTIL's SEC filings can be seen here. And to visit PRECISION BIOSCIENCES INC's official web site, go to

DTIL Valuation Summary

  • In comparison to the median Healthcare stock, DTIL's price/earnings ratio is 107.65% lower, now standing at -1.5.
  • DTIL's price/sales ratio has moved down 75 over the prior 42 months.

Below are key valuation metrics over time for DTIL.

Stock Date P/S P/B P/E EV/EBIT
DTIL 2022-09-23 3.6 1.3 -1.5 0.2
DTIL 2022-09-22 3.8 1.4 -1.5 0.2
DTIL 2022-09-21 4.0 1.5 -1.6 0.1
DTIL 2022-09-20 4.1 1.5 -1.7 0.0
DTIL 2022-09-19 4.4 1.6 -1.8 -0.1
DTIL 2022-09-16 4.5 1.6 -1.8 -0.1

DTIL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DTIL has a Quality Grade of C, ranking ahead of 57.32% of graded US stocks.
  • DTIL's asset turnover comes in at 0.5 -- ranking 82nd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows DTIL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.500 1 -1.846
2021-03-31 0.176 1 -3.839
2020-12-31 0.135 1 -3.174
2020-09-30 0.109 1 -3.116
2020-06-30 0.087 1 -3.034
2020-03-31 0.097 1 -2.717

DTIL Price Target

For more insight on analysts targets of DTIL, see our DTIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.13 Average Broker Recommendation 1.45 (Moderate Buy)

DTIL Stock Price Chart Interactive Chart >

Price chart for DTIL

DTIL Price/Volume Stats

Current price $1.30 52-week high $11.73
Prev. close $1.31 52-week low $1.11
Day low $1.30 Volume 403,600
Day high $1.41 Avg. volume 1,612,725
50-day MA $1.59 Dividend yield N/A
200-day MA $3.00 Market Cap 144.06M

Precision BioSciences, Inc. (DTIL) Company Bio

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

DTIL Latest News Stream

Event/Time News Detail
Loading, please wait...

DTIL Latest Social Stream

Loading social stream, please wait...

View Full DTIL Social Stream

Latest DTIL News From Around the Web

Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.

Trade Alert: The Chief Financial Officer Of Precision BioSciences, Inc. (NASDAQ:DTIL), John Kelly, Has Just Spent US$60k Buying 38% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Precision BioSciences, Inc. ( NASDAQ:DTIL...

Yahoo | September 28, 2022

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

DURHAM, N.C., September 22, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

Yahoo | September 22, 2022

Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

DURHAM, N.C., September 07, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Yahoo | September 7, 2022

Precision BioSciences Announces Senior Leadership Organizational Changes

DURHAM, N.C., September 02, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO).

Yahoo | September 2, 2022

Analysts Offer Insights on Healthcare Companies: Albireo Pharma (ALBO), Precision BioSciences (DTIL) and Ayala Pharmaceuticals (AYLA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma (ALBO – Research Report), Precision BioSciences (DTIL – Research Report) and Ayala Pharmaceuticals (AYLA – Research Report) with bullish sentiments. Albireo Pharma (ALBO) In a report released today, Andreas Argyrides from Wedbush maintained a Buy rating on Albireo Pharma, with a price target of $61.00. The company's shares closed last Monday at $24.93. According to, Argyrides is a 3-star analyst with an average return of -6.7% and a 42.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

Catie Powers on TipRanks | August 16, 2022

Read More 'DTIL' Stories Here

DTIL Price Returns

1-mo -17.72%
3-mo -15.03%
6-mo -61.08%
1-year -88.85%
3-year -82.71%
5-year N/A
YTD -82.43%
2021 -11.27%
2020 -39.96%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5036 seconds.